Have your own idea? Try our Stock Screener
Chinese (SSE) Biotech Industry Analysis
UpdatedJan 07, 2026
DataAggregated Company Financials
Companies74
- 7D4.1%
- 3M-5.5%
- 1Y13.5%
- YTD0.6%
Over the last 7 days, the Biotech industry has risen 4.1%, driven by gains in BeBetter Med and Dizal (Jiangsu) Pharmaceutical of 23% and 11%, respectively. In the same time, HOB Biotech GroupLtd was down 5.6%. In the last 12 months, the industry was up 14%. As for the next few years, earnings are expected to grow by 43% per annum.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 07 Jan 2026 | CN¥954.1b | CN¥106.1b | CN¥3.8b | 48.4x | 252.9x | 9x |
| Fri, 05 Dec 2025 | CN¥955.3b | CN¥106.1b | CN¥3.8b | 50.3x | 253.2x | 9x |
| Sun, 02 Nov 2025 | CN¥1.0t | CN¥106.2b | CN¥4.0b | 51.7x | 253.5x | 9.5x |
| Tue, 30 Sep 2025 | CN¥957.5b | CN¥107.5b | CN¥5.0b | 49.5x | 190x | 8.9x |
| Thu, 28 Aug 2025 | CN¥1.0t | CN¥108.7b | CN¥5.8b | 42x | 174.5x | 9.3x |
| Sat, 26 Jul 2025 | CN¥962.7b | CN¥112.9b | CN¥8.2b | 41.9x | 116.9x | 8.5x |
| Mon, 23 Jun 2025 | CN¥852.8b | CN¥113.0b | CN¥8.3b | 36.4x | 102.9x | 7.5x |
| Wed, 21 May 2025 | CN¥837.4b | CN¥113.1b | CN¥8.3b | 35.5x | 101.2x | 7.4x |
| Fri, 18 Apr 2025 | CN¥835.9b | CN¥135.1b | CN¥11.7b | 31.2x | 71.4x | 6.2x |
| Sun, 16 Mar 2025 | CN¥867.5b | CN¥136.3b | CN¥11.6b | 32.4x | 75x | 6.4x |
| Tue, 11 Feb 2025 | CN¥837.2b | CN¥136.0b | CN¥10.8b | 34.5x | 77.8x | 6.2x |
| Thu, 09 Jan 2025 | CN¥795.5b | CN¥136.0b | CN¥10.8b | 32.8x | 73.9x | 5.8x |
| Sat, 07 Dec 2024 | CN¥902.9b | CN¥136.0b | CN¥10.8b | 34.5x | 83.9x | 6.6x |
| Mon, 04 Nov 2024 | CN¥898.8b | CN¥141.7b | CN¥11.2b | 36.8x | 80.2x | 6.3x |
| Wed, 02 Oct 2024 | CN¥966.1b | CN¥154.1b | CN¥14.5b | 39.2x | 66.9x | 6.3x |
| Fri, 30 Aug 2024 | CN¥777.3b | CN¥160.5b | CN¥16.7b | 29.8x | 46.4x | 4.8x |
| Sun, 28 Jul 2024 | CN¥800.0b | CN¥161.1b | CN¥17.3b | 30.1x | 46.2x | 5x |
| Tue, 25 Jun 2024 | CN¥835.1b | CN¥161.1b | CN¥17.3b | 31.4x | 48.3x | 5.2x |
| Thu, 23 May 2024 | CN¥941.1b | CN¥161.1b | CN¥17.3b | 38.7x | 54.5x | 5.8x |
| Sat, 20 Apr 2024 | CN¥914.4b | CN¥161.3b | CN¥20.3b | 35x | 45.1x | 5.7x |
| Mon, 18 Mar 2024 | CN¥1.0t | CN¥165.3b | CN¥21.9b | 38.3x | 47.1x | 6.2x |
| Wed, 14 Feb 2024 | CN¥955.7b | CN¥167.9b | CN¥21.4b | 31.9x | 44.6x | 5.7x |
| Fri, 12 Jan 2024 | CN¥1.1t | CN¥167.9b | CN¥21.4b | 38.8x | 49.5x | 6.3x |
| Sun, 10 Dec 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 39.7x | 52.3x | 6.7x |
| Tue, 07 Nov 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 40.7x | 51.7x | 6.6x |
| Thu, 05 Oct 2023 | CN¥1.1t | CN¥170.9b | CN¥25.2b | 42.6x | 41.7x | 6.2x |
| Sat, 02 Sep 2023 | CN¥1.0t | CN¥171.2b | CN¥25.3b | 38.5x | 40.1x | 5.9x |
| Mon, 31 Jul 2023 | CN¥1.1t | CN¥177.4b | CN¥29.9b | 40.4x | 37.5x | 6.3x |
| Wed, 28 Jun 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 37.7x | 36.3x | 6x |
| Fri, 26 May 2023 | CN¥1.2t | CN¥177.7b | CN¥29.6b | 43.9x | 39.1x | 6.5x |
| Sun, 23 Apr 2023 | CN¥1.2t | CN¥187.2b | CN¥36.5b | 40.2x | 33.9x | 6.6x |
| Tue, 21 Mar 2023 | CN¥1.2t | CN¥179.0b | CN¥35.8b | 43.7x | 34x | 6.8x |
| Thu, 16 Feb 2023 | CN¥1.3t | CN¥179.6b | CN¥37.9b | 42.5x | 34.5x | 7.3x |
| Sat, 14 Jan 2023 | CN¥1.3t | CN¥175.6b | CN¥37.9b | 41.9x | 34.3x | 7.4x |
Price to Earnings Ratio
34.3x
Current Industry PE
- Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 253x which is higher than its 3-year average PE of 78.9x.
- The 3-year average PS ratio of 6.7x is lower than the industry's current PS ratio of 9.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 54% per year over the last three years,
- Revenues have also declined 15% per year.
- This means overall sales from these companies are declining and profits are subsequently falling as well.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 3.38% | |
| Healthcare | 4.12% | |
| Biotech | 4.06% | |
| Biotech | 4.06% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688759 BeBetter Med | CN¥41.40 | 42.5% +CN¥5.6b | n/a | PB64.2x | |
| 688765 Wuhan Healthgen Biotechnology | CN¥78.16 | 13.1% +CN¥3.2b | n/a | PS984.1x | |
| 688382 InventisBio | CN¥32.31 | 18.6% +CN¥2.9b | 144.8% | PS103.5x | |
| 688192 Dizal (Jiangsu) Pharmaceutical | CN¥63.47 | 10.2% +CN¥2.7b | 66.1% | PS48.2x | |
| 688062 Mabwell (Shanghai) Bioscience | CN¥45.20 | 17.5% +CN¥2.7b | 151.5% | PS28.9x |